Center for Cancer Immune Therapy (CCIT)
The
aim of CCIT is to improve our ability to bridge the gap between
discovery and clinical implementation in the field of cancer
immunotherapy. CCIT has a focus on development of immunological
treatment of cancer, and has a research profile based on equally
weighted experimental and clinical projects facilitating quick clinical
implementation of new immunotherapies e.g. anti-CTLA4. It is the
European leading centre for use of tumour infiltrating lymphocytes (TIL)
for adoptive T-cell therapy (ACT) for metastatic melanoma. CCIT
provides the infrastructure of certified clinical grade laboratory for
preparation of therapeutic cellular products and evaluations of immune
responses.
The laboratory has extensive experience in production
of both T-cells and DCs (including mRNA transfection) for clinical use.
We also perform characterization of tumour antigens recognized by T
cells, studies of T cell and dendritic cell (DC) biology and
interactions, and biological monitoring of immune therapies of cancer,
e.g. vaccination/DC trials and ACT.
CCIT - homepage